Augere Medical AS, a pioneering Norwegian medical device company dedicated to enhancing the accuracy of colorectal cancer screenings, has successfully raised an impressive $2.1 million in its latest funding round. Founded in 2018, Augere's mission is to leverage cutting-edge Artificial Intelligence (AI) technology to improve polyp detection rates through its innovative product, the PolypAID System. In collaboration with leading colonoscopists and the esteemed research group at Simula, the PolypAID System analyzes real-time video streams during colonoscopy procedures, assisting physicians in making informed decisions to significantly enhance patient outcomes. The name "Augere," rooted in Latin and meaning "to increase," reflects the company's commitment to growth, both in technological advancements and patient health outcomes. This latest funding will be instrumental in further advancing the PolypAID system's development, allowing Augere to refine its technology and expand its operational capabilities. The company is deeply committed to implementing transparent AI solutions that prioritize quality, innovation, care, agility, and results—values that resonate with both patients and healthcare professionals. As Augere Medical forges ahead, it remains dedicated to its vision of partnering with global leaders in clinical and technical research to transform cancer screening and treatment, ultimately making lives better. With this fresh injection of capital, Augere is now positioned to realize its ambitious goals and continue its journey toward delivering confident outcomes for patients and healthcare providers alike.










.png&w=3840&q=75)


